| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.38 | 2e-12 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.27 | 8e-11 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-08 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.28 | 2e-07 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.18 | 4e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.25 | 8e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.24 | 1e-05 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-05 |